Clinical Trial

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic dermatitis and patients with chronic pruritus. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-1310? How long does ATTO-1310 stay in the body after dosing? Researchers will compare ATTO-1310 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-1310 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2025-01-15; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Status change: Not Yet Recruiting → Recruiting 2025-01-22
Trial Details
NCT Number NCT06787586
Lead Sponsor Attovia Therapeutics Inc
Conditions Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Enrollment 108 participants
Start Date 2025-01-14
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-03-05